Investigating how PHR signaling affects neurodegeneration related to tau protein.
Official title: The role of PHR signaling in tauopathy-related neurodegeneration
Funded at Florida Institute of Technology · NIH-10875118 · Data updated 2026-11-12
This study is looking at how certain proteins in our cells can cause brain diseases like Alzheimer's, using tiny worms to help find new ways to stop or slow down these conditions, which could lead to better treatments for people with dementia.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida Institute of Technology NIH-funded |
| Lab location | 1 site (Melbourne, United States) |
| Project start | September 17, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $389,851 |
| NIH project number | 1R15NS137207-01 |
| Project ID | NIH-10875118 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for or diagnosed with neurodegenerative diseases, particularly those with symptoms related to tauopathies.
✕Less likely to help
Patients with neurodegenerative diseases not related to tau protein aggregation may not benefit from this research.
What this research studies
This research focuses on understanding the cellular and molecular mechanisms behind neurodegenerative diseases, particularly those related to tau protein aggregation, which is linked to conditions like Alzheimer's disease. By using a model organism, C. elegans, the researchers aim to uncover the role of the RPM-1 signaling network in neuronal degeneration. The study will involve genetic analysis to identify new targets for potential therapies that could halt or slow down the progression of neurodegenerative diseases. This approach may lead to earlier diagnosis and more effective treatments for patients suffering from dementia.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that prevent or slow the progression of neurodegenerative diseases.
How similar studies have gone: Previous research has shown promise in targeting tau protein and its signaling pathways, indicating potential for success in this novel approach.
Where this research is happening
-
Florida Institute of Technology
Melbourne, United States Active
Researchers
- Principal investigator: Borgen, Melissa — Florida Institute of Technology
- Study coordinator: Borgen, Melissa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.